News

2014 WGND Annual Meeting, Barcelona, Oct. 29, 15h-19h

21 Sep 2014
by Working Group
Announcements Events Front Lines of TB R&D Uncategorized
conferences and meetings drug discovery r&d stop tb the union wgnd

We invite you to join us for the Stop TB Partnership Working Group on New Drugs’ Annual Meeting 2014 at AC Hotel Barcelona Forum, Barcelona, Spain, on Wednesday, Oct. 29th from 15:00 to 19:00.
This meeting is held before the 45th Union World Conference on Lung Health (The Union). During the meeting we will review and discuss progress of projects in the Global TB Drug Pipeline and Drug Discovery Portfolio, the new Global Plan development, review WGND 2014 activities, and discuss other relevant topics. Representatives from pharmaceutical companies, research consortia and organizations, NGOs and academia will be participating.

An agenda will be posted in the next few weeks. Light refreshments will be served.

Registration is free.

If you have any questions or want to register, send an e-mail to wgnd@newtbdrugs.org

Explore. Learn. Join the Conversation at www.newtbdrugs.org.

More News
22 Jul 2024

With NIH Funding, A New Consortium Aims to Improve TB Treatment

The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024

WHO Released Its Updated Bacterial Priority Pathogens List

On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024

Most Robust TB Drug Pipeline in History

For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...